UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

Zoetis Inc.

[ ZTS ]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

3. Date of Earliest Transaction

(Month/Day/Year)

06/24/2013

4. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year)

2A. Deemed Execution Date, if any

(Month/Day/Year)

3. Transaction Code (Instr.

8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

Amount

(A) or (D)

Price

Class A Common Stock

06/24/2013

400,985,000

(1)(3)

400,985,000

Class A Common Stock

06/24/2013

400,985,000

(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date

(Month/Day/Year)

3A. Deemed Execution Date, if any

(Month/Day/Year)

4. Transaction Code (Instr.

8)

5.

Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.

3, 4 and 5)

6. Date Exercisable and Expiration Date

(Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr.

3 and 4)

8. Price of Derivative Security (Instr.

5)

9.

Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.

4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

11. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Class B Common Stock

(3)

06/24/2013

400,985,000

(3)

(3)

Class A Common Stock

400,985,000

$0

Explanation of Responses:

1. The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price.

2. Pfizer Inc. ("Pfizer") disposed of 400,985,000 shares of Class A Common Stock of Zoetis Inc. ("Class A Common Stock") in exchange for 405,117,195 shares of Pfizer common stock pursuant to a registered exchange offer to Pfizer common stockholders. The final exchange ratio for the exchange offer was 0.9898 shares of Class A Common Stock per share of Pfizer common stock accepted in the exchange offer. As a result of the exchange offer, Pfizer has disposed of its entire equity interest in the Issuer. The closing price of Pfizer common stock on the New York Stock Exchange on June 21, 2013, the trading day immediately preceding the day on which Pfizer accepted Pfizer shares that had been validly tendered and not validly withdrawn,was $28.46.

3. The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date.

/s/ Matthew Lepore, Vice President and Corporate Secretary on behalf of Pfizer Inc.

06/26/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.